This study is a 2 period open label study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 3 months and 12 years. Dasiglucagon will be administered as a subcutaneous infusion. To be eligible subjects are to be having at least 3 or more hypoglycemic events a week, and are to have undergone a pancreatectomy for hyperinsulinism or are being treated with a non surgical approach, because they were not eligible for pancreatic surgery.
Congenital Hyperinsulinism Center Clinical Studies
1 - 2 of 2
Our team is working on a study to better understand neurological problems, including seizures and developmental delays, that occur in many individuals with HI /HA syndrome. The study involves a one day visit to The Children’s Hospital of Philadelphia and The University of Pennsylvania for a specialized magnetic resonance imaging scan (MRI) of the brain, an electroencephalogram (EEG), blood draw, and completion of questionnaires to evaluate development and behavior. The entire study visit is expected to take about four hours. If you are interested in learning more, please contact us at HIResearch@email.chop.edu.